Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESAX-HTN: CS-3150 vs Eplerenone in Essential Hypertension
NCT02890173Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of esaxerenone in essential hypertension (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Change from baseline in sitting systolic blood pressure at 12 weeks and Change from baseline in sitting diastolic blood pressure at 12 weeks. Started Sep 2016; status: completed.
02
Drugs
esaxerenone
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT02890173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02890173.